Clearside Biomedi (CLSD) Stock Price, Quote & News

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 270 3631

Fax: 678 270 4033

Website: clearsidebio.com

Address:

900 North Point Parkway, Suite 200, Alpharetta, United States

rando321456 Aug. 25 at 2:51 PM

$CLSD $RGNX Regenx has the DR pivotal initiating in 2025 in their latest presentation. They have a little green check mark next to this milestone so would bet they get the first patient dosed this year.

1 · Reply

Knowledgeworthmore Aug. 25 at 2:28 PM

$BTAI $PGEN $ADAP $CLSD more info about clsd pipeline https://clearsidebio.com/pipeline/ do your research, know what you investing for.

0 · Reply

Knowledgeworthmore Aug. 25 at 2:25 PM

$CLSD added some l can tell future is bright for this.

0 · Reply

ChasmCapital Aug. 23 at 9:22 AM

$CLSD Clearside Biomedical Inc is a clinical stage ophthalmology company with delivery technology

0 · Reply

maphere Aug. 22 at 5:33 PM

$CLSD $OCUL $EYPT At 21:45 Dr. Peter Kaiser who is working with OCUL says that 6 months is all physicians want from TKIs, b/c they want to see the patients no later than this time frame so 9 months or 12 months doesn't seem to add value...but I'll let the OCUL guys speak into this point. But, if this is the case, then I'd say out of the 3 TKIs it will come down to safety and efficacy...and of course, CLSD has to get back into the race. https://www.youtube.com/watch?v=URyNFBj5Mvg

3 · Reply

Clifden Aug. 22 at 4:35 PM

$CLSD Meanwhile back at CLSD headquarters 🤷‍♂️🔎

0 · Reply

Leyloo007 Aug. 22 at 2:17 PM

$CLSD

0 · Reply

maphere Aug. 20 at 8:32 PM

$CLSD $OCUL $EYPT $RGNX July 31,2025 The Retina Radar With Dr. Arshad Khanani: Sustained Delivery With Dr. David Almeida Start at 12:00, pay attention at 16:00 and 20:50 https://ophthalmology.libsyn.com/the-retina-radar-with-dr-arshad-khanani-sustained-delivery-with-dr-david-almeida

1 · Reply

wishpotion Aug. 20 at 2:47 PM

$CLSD Is the worst part behind us ? I do think so, because there is not much speculation room left now. The course is set very clear and the only question left is what can be sold, when, to which conditions. Also the timeframe till there needs to happen something is no longer as Q1 2026 according to financial considerations. The only part what is making me sceptical is the question why some deal was not doable , even not to ideal conditions , before those drastical steps of letting their employee go, had to happen ? My question here is, does the former employee have some rights even when not actively working anymore for CLSD to benefit from some future deals ? If this is the case, I would interpret it this way that before that steps were done the CLSD management followed the plan to find a partnership deal only. Now that this was not succesful Plan B is happening now selling what is possible and providing this way some thank you presents to them.

2 · Reply

maphere Aug. 18 at 2:34 PM

$CLSD Umm, interesting, Kriya Therapeutics, a non-publicly traded company who focuses on the SCS and preclinical GA... Yes, currently using Everads injector but let's assume they were initially rejected by CLSD b/c of RGNX partnership but maybe now the door is open. _________________ "Kriya Therapeutics has raised $313.3 million in a funding round that the North Carolina–based gene therapy maker disclosed Friday in an SEC filing. The regulatory document did not specify what the funds will be used for, nor did it identify the sources of the funding, only stating that two investors participated in the financing push." https://www.biospace.com/business/gene-therapy-specialist-kriya-raises-313m

2 · Reply

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Jul 17, 2025, 7:05 AM EDT - 5 weeks ago

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Jun 17, 2025, 7:05 AM EDT - 2 months ago

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

May 21, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

May 14, 2025, 4:05 PM EDT - 3 months ago

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

May 8, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 1, 2025, 7:05 AM EDT - 4 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Apr 1, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:31 PM EDT - 5 months ago

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Mar 27, 2025, 4:05 PM EDT - 5 months ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 20, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Mar 12, 2025, 7:05 AM EDT - 5 months ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Mar 6, 2025, 7:05 AM EST - 6 months ago

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Feb 20, 2025, 7:05 AM EST - 6 months ago

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Feb 10, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Feb 4, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Jan 28, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Jan 22, 2025, 7:05 AM EST - 7 months ago

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Dec 19, 2024, 7:05 AM EST - 8 months ago

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Nov 25, 2024, 7:05 AM EST - 9 months ago

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Nov 12, 2024, 8:37 PM EST - 10 months ago

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 9:05 AM EST - 10 months ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Nov 6, 2024, 7:05 AM EST - 10 months ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:05 AM EST - 10 months ago

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Oct 31, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Oct 22, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Oct 9, 2024, 6:30 AM EDT - 11 months ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 1, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Jul 24, 2024, 11:23 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Jul 22, 2024, 12:00 PM EDT - 1 year ago

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Jul 11, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Jun 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Jun 25, 2024, 12:54 PM EDT - 1 year ago

Why Is Clearside Biomedical Stock Gaining Today?

Jun 12, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

May 21, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 9, 2024, 9:14 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:15 PM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Apr 16, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Apr 2, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 13, 2024, 12:47 AM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:05 AM EST - 1 year ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Feb 7, 2024, 8:00 AM EST - 1 year ago

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

rando321456 Aug. 25 at 2:51 PM

1 · Reply

Knowledgeworthmore Aug. 25 at 2:28 PM

$BTAI $PGEN $ADAP $CLSD more info about clsd pipeline https://clearsidebio.com/pipeline/ do your research, know what you investing for.

0 · Reply

Knowledgeworthmore Aug. 25 at 2:25 PM

$CLSD added some l can tell future is bright for this.

0 · Reply

ChasmCapital Aug. 23 at 9:22 AM

$CLSD Clearside Biomedical Inc is a clinical stage ophthalmology company with delivery technology

0 · Reply

maphere Aug. 22 at 5:33 PM

3 · Reply

Clifden Aug. 22 at 4:35 PM

$CLSD Meanwhile back at CLSD headquarters 🤷‍♂️🔎

0 · Reply

Leyloo007 Aug. 22 at 2:17 PM

$CLSD

0 · Reply

maphere Aug. 20 at 8:32 PM

1 · Reply

wishpotion Aug. 20 at 2:47 PM

2 · Reply

maphere Aug. 18 at 2:34 PM

2 · Reply

JaumeIII Aug. 17 at 3:47 PM

$CLSD with a change in ownership, what does HCR have to be paid? A minimum number or the whole amount?

2 · Reply

JaumeIII Aug. 17 at 3:11 PM

$CLSD I wonder what Victor has been up to…

0 · Reply

wishpotion Aug. 15 at 10:51 AM

$CLSD That delisting information is just the formal needed info step, no more no less we all were aware of. They will be able to stay listed as long as needed with actual steps already done. That Gibney resignated is for me a additional very clear hint that the company will not exist further in this form relative soon. Also nothing really astonishing anymore. Open question is still, when and to which extend this will happen and who will continue with what part of their IP. If there will be a tiny CLSD part left to enable diverse partner programs to proceed till finished and vanish afterwards or if someone takes over anything means also their actual contractual responsibilities, we will see.

0 · Reply

maphere Aug. 15 at 4:46 AM

$CLSD probably worth a listen... I'm getting shut eye first... https://www.linkedin.com/posts/kylelahucik_vc-firm-hatteras-closes-200m-for-life-sciences-activity-7361370618006552576-7b0I?utm_source=share&utm_medium=member_android&rcm=ACoAAAXObpMB_ohGxf74o-pkIrOKz0heKnRRmuk

1 · Reply

maphere Aug. 15 at 4:02 AM

$CLSD 2 new patents: European patent: 8/13/25 File Date: 2013-11-08 Pub Date: 2025-08-13 METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS Abstract Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles. https://www.patentguru.com/EP4566672A3

1 · Reply

valueforme Aug. 14 at 9:17 PM

$CLSD 10 cents?

1 · Reply

Investoryanstocktwits Aug. 14 at 8:49 PM

$CLSD well we got the delisting notice which I think we expected and RS to hopefully get us in compliance. News is Gibney is leaving (was weird him being CFO at a partner and chair of clearside) and we get Thorp back. zNot of fan of Thorp but Im not sure who else at this stage would have bee na option. Would have prefered Gibney to stay even with bad optics. I just hope they are set at selling and Piper is getting bids because I dont have a lot of confidence on the board. But still have valuable assets and partnerships.

1 · Reply

maphere Aug. 14 at 3:25 PM

$CLSD My assumption is CLSD has preemptively provided Nasdaq with a plan to become compliant (reverse stock...), which is why we haven't heard from Nasdaq with a delisting notice which we could have seen as early as Aug. 7th. I checked with Grok and this a definite possibility. I think we'll get another 180 days.

3 · Reply

UgoGreg Aug. 14 at 2:21 PM

$CLSD https://youtu.be/nAnV2o6Ge-c

0 · Reply

UgoGreg Aug. 14 at 2:21 PM

$CLSD

0 · Reply

maphere Aug. 13 at 5:46 PM

$CLSD EURetina2025 Sept. 4-7th, topics re: Suprachoroidal: __________________ Intravitreal, subretinal and suprachoroidal gene therapy delivery: common vectors, risks, and benefits of Suprachoroidal gene therapy for diabetic retinopathy (ALTITUDE study) Suprachoroidal Approaches for Subretinal Drug Delivery: Devices, Benefits, and Complication Risks Suprachoroidal Space as a Therapeutic Gateway: A New Frontier in Drug Delivery A Decade-Long Review of the Evolution of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update https://euretina.org/paris-2025/programme-overview-list-view/

1 · Reply

JaumeIII Aug. 13 at 5:23 PM

$CLSD At this point it is just a matter of waiting and seeing what the different parts are worth...keep in mind Arctic vision sold the Xipere (Arcatus) China rights to Santen for 30 million, almost the same price as the current clsd market cap. A little crazy!

3 · Reply

Market Cap	31.97M
Revenue (ttm)	1.66M
Net Income (ttm)	-34.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,069.28%
Debt to Equity Ratio	0.00

Volume	635,095
Avg Vol	5,431,834
Day's Range	N/A - N/A
Shares Out	78.51M
Stochastic %K	20%
Beta	2.08
Analysts	Sell
Price Target	$3.75